desidustat   Click here for help

GtoPdb Ligand ID: 12285

Synonyms: EXAMPLE 2 [WO2014102818A1] | Oxemia® | ZYAN-1 | ZYAN1
Compound class: Synthetic organic
Comment: Desidustat (ZYAN1) is an orally bioavailable inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzymes (PHD1, PHD2, and PHD3; genes EGLN2, EGLN1 and EGLN3 respectively) [5]. It was developed as a strategy to promote erythropoietin (EPO) synthesis and erythropoiesis by stabilising HIF-α transcription factors, as a mechanism to treat anemia associated with chronic diseases. Orally active HIF-PH inhibitors are being exploited as alternatives to injectable erythropoietin stimulating drugs, such as epoetin and darbepoetin, to treat anemia.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 117.86
Molecular weight 332.1
XLogP 2.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)CNC(=O)c1c(O)c2ccccc2n(c1=O)OCC1CC1
Isomeric SMILES C1CC1COn1c2ccccc2c(c(c1=O)C(=O)NCC(=O)O)O
InChI InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)
InChI Key IKRKQQLJYBAPQT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Desidustat (ZYAN1) was advanced to clinical studies to evaluate its potential as a treatment for anemia in patients with chronic kidney disease and chemotherapy-induced anemia. First approval of desidustat was granted in India in March 2022 [3], as a treatment for chronic kidney disease-induced anaemia.
Desidustat has also been tested for efficacy as a pharmacological intervention for anaemia associated with COVID-19.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04463602 Desidustat in the Management of COVID-19 Patients Phase 2 Interventional Zydus Lifesciences Limited
NCT04667533 Desidustat in the Treatment of Chemotherapy Induced Anemia Phase 1 Interventional Zydus Lifesciences Limited
NCT04012957 Desidustat in the Treatment of Anemia in CKD Phase 3 Interventional Zydus Lifesciences Limited The DREAM-ND study 1
NCT04215120 Desidustat in the Treatment of Anemia in CKD on Dialysis Patients Phase 3 Interventional Zydus Lifesciences Limited The DREAM-D study 4